Our CEO, Joseph C. Sardano, talks to TWST about Sensus Healthcare’s corporate strategy, investment thesis and growth opportunities — and our superficial radiation therapy and Directional Anisotropic Radiation Therapy (ART) platforms.
98.7%+
Non Reoccurrence Rate
No anesthesia, cutting, bleeding, stitching or pain
No downtime or lifestyle restrictions
Super cosmesis, no unsightly scarring
No need for post-treatment reconstructive surgeries
